Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.47 |
| ▸ | FABP7 | O15540 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | MDM4 | O15151 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7809928 | 0.89 | KMT2A (0.52) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL10110895 | 0.86 | KMT2A (0.51) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL29456842 | 0.86 | KMT2A (0.51) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL28309128 | 0.85 | KMT2A (0.49) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL14689743 | 0.85 | KMT2A (0.49) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL15874638 | 0.85 | KMT2A (0.49) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL15874406 | 0.85 | KMT2A (0.49) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL18286329 | 0.85 | KMT2A (0.46) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL8453047 | 0.84 | KMT2A (0.50) | KMT2AFABP5FABP7CA1CA2 | |
| SCHEMBL31517102 | 0.84 | KMT2A (0.50) | KMT2AFABP5FABP7CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025124486-A1 | GLP-1 RECEPTOR COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF | 深圳信立泰药业股份有限公司 | 2025-06-19 | — | — | WO | disclosed |
| WO-2025098422-A1 | MULTI-RECEPTOR CO-AGONIST COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 深圳信立泰药业股份有限公司 | 2025-05-15 | — | — | WO | disclosed |
| WO-2025092778-A1 | GLP-1 COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 深圳信立泰药业股份有限公司 | 2025-05-08 | — | — | WO | disclosed |
| CN-119912551-A | Deuterated GLP-1 compound and preparation method and application thereof | 深圳信立泰药业股份有限公司 | 2025-05-02 | — | — | CN | disclosed |
| WO-2023129518-A1 | TUBULYSINS AND PROTEIN-TUBULYSIN CONJUGATES | REGENERON PHARMACEUTICALS, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
| US-20150099808-A1 | AMPHIPHILIC COPOLYMERS AND COMPOSITIONS CONTAINING SUCH POLYMERS | NIRVANA'S TREE HOUSE B.V. (NL) | 2015-04-09 | — | — | US | disclosed |
| US-8841257-B2 | Inhibitors of STAT3 and uses thereof | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-09-23 | — | — | US | disclosed |
| US-20120035114-A1 | INHIBITORS OF STAT3 AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-02-09 | — | — | US | disclosed |
| US-8030445-B2 | Glycopeptide derivative | THERAVANCE, INC. (US) | 2011-10-04 | — | — | US | disclosed |
| CN-102186812-A | Methods for preparing fluoroalkyl arylsulfinyl compounds and fluorinated compounds thereto | UBE INDUSTRIES | 2011-09-14 | — | — | CN | disclosed |
| US-6518242-B1 | Derivatives of glycopeptide antibacterial agents | THERAVANCE, INC. | 2003-02-11 | — | — | US | disclosed |
| US-20030008812-A1 | Glycopeptide derivatives | THERAVANCE, INC. | 2003-01-09 | — | — | US | disclosed |
| US-6455669-B1 | GLYCOPROTEIN FOR USE IN THE TREATMENT AND PREVENTION OF BACTERIAL INFECTIONS | THERAVANCE, INC. | 2002-09-24 | — | — | US | disclosed |
| US-6444786-B1 | BACTERICIDES | ADVANCED MEDICINE, INC. | 2002-09-03 | — | — | US | disclosed |
| US-6392012-B1 | COMPOUND FOR USE IN TREATMENT AND PREVENTION OF BACTERIAL INFECTION | ADVANCED MEDICINE, INC. | 2002-05-21 | — | — | US | disclosed |
| EP-1140993-A1 | GLYCOPEPTIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Advanced Medicine, Inc. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2001057071-A2 | GLYCOPEPTIDE DERIVATIVES HAVING ANTIBIOTIC ACTIVITY | ADVANCED MEDICINE, INC. (US) | 2001-08-09 | — | — | WO | disclosed |
| EP-1060189-A1 | DERIVATIVES OF GLYCOPEPTIDE ANTIBACTERIAL AGENTS | Advanced Medicine, Inc. (US) | 2000-12-20 | — | — | EP | disclosed |
| WO-2000039156-A1 | GLYCOPEPTIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | ADVANCED MEDICINE, INC. (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-1999042476-A1 | NOVEL ANTIBACTERIAL AGENTS | ADVANCED MEDICINE, INC. (US) | 1999-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008812-A1 | Glycopeptide derivatives | MGAT3, GYPA, GIPR | KMT2A 4608/4885FABP5 2718/4885FABP7 3062/4885 |
| US-20150099808-A1 | AMPHIPHILIC COPOLYMERS AND COMPOSITIONS CONTAINING SUCH POLYMERS | GLUL, ASNS, ARGLU1 | KMT2A 1839/4885FABP5 1864/4885FABP7 505/4885 |
| US-20120035114-A1 | INHIBITORS OF STAT3 AND USES THEREOF | STAT3, JAK2, STAT6 | KMT2A 2506/4885FABP5 2080/4885FABP7 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.